Lakefront Biotherapeutics American Depositary Shares
LKFT
81 hedge funds and large institutions have $450M invested in Lakefront Biotherapeutics American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 41 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
1.59% more ownership
Funds ownership: 11.45% → 13.04% (+1.6%)
13% less capital invested
Capital invested by funds: $517M → $450M (-$67.4M)
26% less funds holding
Funds holding: 109 → 81 (-28)
42% less call options, than puts
Call options by funds: $21.8M | Put options by funds: $37.8M
66% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$92.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$66.5M |
| 3 |
6CM
683 Capital Management
New York
|
+$39.7M |
| 4 |
O
OrbiMed
New York
|
+$29.2M |
| 5 |
JP Morgan Chase
New York
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$119M |
| 2 |
DM
Deerfield Management
New York
|
-$45.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$35.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$11.4M |
LKFT Hedge Fund Activity: Q3 2021 in Review
81 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2021, worth a combined $450M — down 13% from $517M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of LKFT and 14 opened new positions — a net loss of 27 holders — while 20 trimmed existing stakes and 31 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $92.5M. The largest seller was Capital International Investors, exiting entirely with an estimated $119M sold.
- 81 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2021, down from 109 in Q2 2021.
- Funds reported $450M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2021, down 13% quarter-over-quarter.
- 14 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2021 and 41 closed out, a net change of -27 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2021 was EcoR1 Capital, an estimated $92.5M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2021 was Capital International Investors, an estimated $119M sold.
Based on aggregated 13F filings for Q3 2021.